SAPPHIRe III in Taiwan－Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families
Recruitment status was Recruiting
|Study Design:||Observational Model: Family-Based
Time Perspective: Retrospective
|Official Title:||Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families－A Follow-up Genetic Study of Taiwan SAPPHIRe Cohort|
|Study Start Date:||October 2006|
|Estimated Study Completion Date:||December 2010|
Blood pressure is a quantitative trait affected by both genetic and environmental factors. Stanford-Asian Pacific Program in Hypertension and Insulin Resistance (SAPPHIRe) is an international genetic study, which intends to map the major genetic loci underlying hypertension in sibpairs of Asian-Pacific Chinese and Japanese origin.
Success in genetic studies may depend on many factors including the selection of the patient population, the identification of intermediate phenotypes, the disease subsets, and the genetic strategy and methodologies employed.
In order to reduce heterogeneity of the genetic and environmental background, we will focus our investigation on the Chinese population. Furthermore, besides the variables associated with insulin resistance, which were collected and studied in year 1 through 5 of SAPPHIRe, some more variables from echocardiographic examination and multi-detector row computed tomography (MDCT) will be collected and studied.
Hypertension is a major risk factor for stroke, myocardial infraction and renal disease. Hypertension often occurs in combination with other metabolic complications such as hyperlipidemia, obesity and insulin resistance. The combined disorder is often called the metabolic syndrome.
Our general approach is to continue analyzing candidate genes as well as perform a complete genome search based on the exiting genome-wide scan data together with old and new phenotype variables. Our objective is to identify susceptible gene for hypertension through incorporating intermediate phenotypes and to find gene markers for developing useful screening tools for the high risk group in order to prevent or early detect cardiovascular disorder patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00631956
|Division of Biostatistics and Bioinformatics, NHRI||Recruiting|
|Miaoli county, Taiwan, 350|
|Contact: Guan Yi Hung, Master 886-37-246166 ext 36145 email@example.com|
|Principal Investigator: Chao Hsiung, PhD|
|Study Director:||Chao Hsiung, PhD||Division of Biostatistics and Bioinformatics, National Health Research Institutes|